Involving A Nucleic Acid Encoding A Receptor, Cytokine, Hormone, Growth Factor, Ion Channel Protein, Or Membrane Transporter Protein Patents (Class 435/6.17)
-
Patent number: 8298756Abstract: Methods of isolating motile cells of interest from an animal tissue is provided. Also provided are methods of determining mRNA or protein expression of a gene in motile cells of interest from an animal tissue. Additionally, methods of determining whether a cancer in a tissue of a mammal is likely to metastasize are provided. Methods are also provided for inhibiting metastasis of a cancer in a tissue of a mammal. Further provided are methods of determining resistance of a motile cancer cell population in an animal tissue to a chemotherapeutic agent.Type: GrantFiled: August 4, 2005Date of Patent: October 30, 2012Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventor: John S. Condeelis
-
Publication number: 20120270890Abstract: Disclosed are new methods for pancreatic ?-cell regeneration and the methods for identifying adult pancreatic endocrine stem cells and the methods for identifying the existence of differentiation processes from adult pancreatic endocrine stem cells toward pancreatic ?-cell fate and a new animal model for pancreatic ?-cell regeneration. The present invention can be utilized in screening and development of new medicines and therapy protocols for diabetes.Type: ApplicationFiled: April 20, 2012Publication date: October 25, 2012Inventors: Cheng-Ho Chung, Fred Levine
-
Publication number: 20120264127Abstract: The present invention provides compositions and methods for simultaneously detecting mutational status and gene copy number. In particular, the present invention provides simultaneous measurement of gene copy number and detection of the L858R and Exon 19 del mutations in a tissue sample.Type: ApplicationFiled: December 30, 2010Publication date: October 18, 2012Inventors: Shalini Singh, Hiro Nitta, Fabien Gaire, Edmundo David Del Valle
-
Publication number: 20120238494Abstract: A method for recognizing and evaluating the presence and function of GnRH receptors on tumor cells including those originating in the brain and/or nervous system and/or the meninges and/or reactive neuroglia cells and/or primitive neuroectodermal tumor cells and/or on Kaposi sarcoma is provided. Furthermore, a method for reducing degenerate GnRH-positive tumor cells and/or for decreasing cellular replication of the above GnRH-positive tumor cells comprising administering to a cell or to a subject a replication decreasing amount of a GnRH agonist and/or GnRH antagonist and/or an erythropoietin agonist, and/or a thrombopoietin agonist, and/or a endothelin antagonist and/or a gonadotropin inhibiting hormone agonist is also provided. Furthermore, a diagnostic kit for detecting GnRH receptors on tumor cells according to the present methods is disclosed.Type: ApplicationFiled: March 27, 2012Publication date: September 20, 2012Inventor: JOHANNES C. VAN GROENINGHEN
-
Publication number: 20120237942Abstract: Marker levels and forms can be modulated in patients having vascular disease when sufficient vascular tissue is removed. The markers can be, e.g., from tissue, blood or lymph. The markers are typically involved in molecular pathways which are in turn modulated. Atherectomy catheters are used for accomplishing sufficient removal of vascular tissue to effect the modulations.Type: ApplicationFiled: May 31, 2012Publication date: September 20, 2012Applicant: TYCO HEALTHCARE GROUP LPInventor: John B. Simpson
-
Patent number: 8268572Abstract: Methods are provided for identifying candidate agents for use in inhibiting expression of certain receptors and ion channels in nociceptors. Also provided are methods for identifying candidates agents for use in inhibiting neurophathic and other types of pain.Type: GrantFiled: March 3, 2006Date of Patent: September 18, 2012Assignees: Dana-Farber Cancer Institute, Inc., The General Hospital CorporationInventors: Qiufu Ma, Chih-Li Chen, Clifford J. Woolf, Daniel C. Broom
-
Patent number: 8268566Abstract: A method for predicting patient responsiveness to rheumatoid arthritis treatments involving altering expression of tumor necrosis factor superfamily (“TNFSF”)-2, TNFSF-8, or TNFSF-15 is disclosed. A method for monitoring the effectiveness of such therapy is also disclosed. Furthermore, a method of screening compounds for use in the treatment of rheumatoid arthritis is disclosed. A method of monitoring the disease state over time in rheumatoid arthritis patients is also disclosed.Type: GrantFiled: November 11, 2008Date of Patent: September 18, 2012Assignees: Hitachi Chemical Research Center, Inc., Hitachi Chemical Co., Ltd.Inventors: Masato Mitsuhashi, Katsuya Endo, Kazuhiko Obara, Hiroshi Izutsu, Shuji Ohta
-
Patent number: 8268618Abstract: The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.Type: GrantFiled: August 16, 2006Date of Patent: September 18, 2012Assignee: Sangamo BioSciences, Inc.Inventors: George Norbert Cox, III, Casey Christopher Case, Stephen P. Eisenberg, Eric Edward Jarvis, Sharon Kaye Spratt
-
Patent number: 8263341Abstract: Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular tastant in a mammal are also described, as are methods for generating novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. Further, methods for stimulating or blocking taste perception in a mammal are also disclosed.Type: GrantFiled: April 22, 2011Date of Patent: September 11, 2012Assignee: Senomyx, Inc.Inventors: Jon Elliot Adler, Sergey Zozulya, Xiadong Li, Shawn O'Connell, Lena Staszewski
-
Publication number: 20120225433Abstract: The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of breast cancer.Type: ApplicationFiled: May 16, 2012Publication date: September 6, 2012Inventors: Melody A. Cobleigh, Steve Shak, Joffre B. Baker, Maureen T. Cronin
-
Patent number: 8236507Abstract: A DNA sequence encoding a protein capable of binding to a tumor necrosis factor receptor-associated factor (TRAF) molecule, TRAF-binding proteins, their isoforms, analogs, fragments and derivatives encoded by the DNA sequence, their methods for the production of the DNA sequences and proteins, and the uses for the DNA sequence and proteins.Type: GrantFiled: February 3, 2009Date of Patent: August 7, 2012Assignee: Yeda Research and Development Co., Ltd.Inventors: David Wallach, Nikolai Malinin, Mark Boldin, Andrei Kovalenko, Igor Mett
-
Patent number: 8227189Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with coronary heart disease and in particular VT and response to drug treatment. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: GrantFiled: February 8, 2011Date of Patent: July 24, 2012Assignee: Celera CorporationInventors: Lance Bare, James J. Devlin, Frits R. Rosendaal, Pieter H. Reitsma, Irene D. Bezemer
-
Patent number: 8221979Abstract: Diagnostic and therapeutic applications for Noonan Syndrome are described. The diagnostic and therapeutic applications are based on certain mutations in a RAS-specific guanine nucleotide exchange factor gene SOS1 or its expression product. The diagnostic and therapeutic applications are also based on certain mutations in a serine/threonine protein kinase gene RAF1 or its expression product thereof. Also described are nucleotide sequences, amino acid sequences, probes, and primers related to RAF1 or SOS1, and variants thereof, as well as host cells expressing such variants.Type: GrantFiled: November 16, 2007Date of Patent: July 17, 2012Assignees: Mount Sinai School of Medicine, The Regents of the University of CaliforniaInventors: Bruce D. Gelb, Marco Tartaglia, Len Pennacchio
-
Patent number: 8206922Abstract: Methods are described for screening a subject for risk of Charcot-Marie-Tooth Disease Type 2A or for diagnosing Charcot-Marie-Tooth disease or a predisposition for developing Charcot-Marie-Tooth disease in a subject, by detecting the presence or absence of a mutation in the mitofusin gene in a biological sample collected from the subject. Methods are also described for detecting the presence of a genetic polymorphism associated with Charcot-Marie-Tooth Disease Type 2A in a sample of patient nucleic acid, by amplifying a mitofusin gene sequence in the patient nucleic acid to produce an amplification product; and identifying the presence of a Charcot-Marie-Tooth Disease Type 2A associated polymorphism in the amplification product.Type: GrantFiled: March 25, 2010Date of Patent: June 26, 2012Assignee: Duke UniversityInventors: Jeffery M. Vance, Stephan Zuchner, Margaret A. Pericak-Vance
-
Patent number: 8206931Abstract: The present invention provides methods and compositions for identifying compounds which modulate cellular glycosylation. The invention further provides methods for treating subjects suffering from or at risk of developing a glycosylation associated disorder.Type: GrantFiled: January 18, 2004Date of Patent: June 26, 2012Assignee: The Johns Hopkins UniversityInventors: Jeffrey D. Rothstein, Alicia Ruggiero
-
Publication number: 20120149785Abstract: A method of estimating sepsis risk in an individual with infection comprises a step of assaying a biological sample from the individual for an IL-2 or IL-7 mRNA value, and correlating the mRNA value with sepsis risk. The IL-2 and IL-7 mRNA values are quantified by absolute quantification of mRNA copy number, wherein the copy numbers are normalised to a house keeping gene and corrected against a calibration curve for serial dilutions of the IL-2 and IL-7 cDNA. The method generally involves a step of assaying a biological sample from the individual for IL-2 and/or IL-7 mRNA values, optionally in combination with mRNA values for other cytokines, and correlating a sum or difference of the values with sepsis risk using a regression analysis curve against outcome.Type: ApplicationFiled: October 9, 2009Publication date: June 14, 2012Applicant: The Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen ElizabeInventors: Thomas Ryan, Mary White, Owen Ross McManus, Dermot Kelleher
-
Patent number: 8198025Abstract: This invention relates to a composition, kit, or DNA chip comprising polynucleotides and antibodies as probes for detecting, determining, or predicting the presence or metastasis of esophageal cancer, and to a method for detecting, determining, or predicting the presence or metastasis of esophageal cancer using the same.Type: GrantFiled: April 6, 2011Date of Patent: June 12, 2012Assignees: Toray Industries, Inc., Kyoto UniversityInventors: Hideo Akiyama, Satoko Kozono, Akira Myomoto, Osamu Nomura, Hitoshi Nobumasa, Yoshinori Tanaka, Shiori Tomoda, Yutaka Shimada, Gozoh Tsujimoto
-
Publication number: 20120142015Abstract: The present invention provides fusion proteins including a green fluorescent protein inserted into the internal amino acid sequence of a G?s protein and further provides method of using the fusion protein construct to follow activation of a G-protein receptor by a candidate drug.Type: ApplicationFiled: October 25, 2011Publication date: June 7, 2012Applicant: The Board of Trustees of The University of IllinoisInventors: Mark Rasenick, Jiang-zhou Yu
-
Publication number: 20120141988Abstract: The present invention discloses a method of cell-line identification comprising one or more of the following steps: (a) analysis of the calmodulin gene; (b) analysis of the Axl receptor tyrosine kinase gene; (c) analysis of an attacin gene; or a combination thereof.Type: ApplicationFiled: February 19, 2010Publication date: June 7, 2012Inventors: Jean-Pol Cassart, Patricia Anne-Laure Lienard
-
Publication number: 20120135409Abstract: There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer. Provided herein are methods for using DNA sequencing to identify personalized biomarkers in patients with autoimmune disease and other conditions. Identified biomarkers can be used to determine the disease state for a subject with an autoimmune disease or other condition.Type: ApplicationFiled: August 19, 2011Publication date: May 31, 2012Applicant: SEQUENTA, INC.Inventors: Malek Faham, Thomas Willis
-
Patent number: 8178299Abstract: A new method is found to determine an increased risk for side effects of an SSRI treatment in a person by genotyping the person for the presence of the 102 C/C DNA sequence in the 5-HT2A receptor gene. This provides for a method to improve the treatment of an SSRI responsive disorder and in particular depression.Type: GrantFiled: April 25, 2011Date of Patent: May 15, 2012Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Greer M. Murphy, Alan F. Schatzberg
-
Publication number: 20120108790Abstract: The present invention is directed to fusion proteins that can be used to assay gene transfer and expression both in vitro and in vivo. The fusion proteins contain a reporter protein, e.g. a somatostatin receptor, fused to a second protein, which may be a protein fusion tag. Alternatively, a fusion protein may be fused to a leader sequence. A leader sequence may localize an expressed protein, e.g. localize a fusion protein to the cell membrane. The invention includes nucleic acids encoding the fusion proteins and methods of assaying for gene expression.Type: ApplicationFiled: September 6, 2011Publication date: May 3, 2012Inventor: Vikas Kundra
-
Patent number: 8168586Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (“CAT”). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.Type: GrantFiled: November 21, 2008Date of Patent: May 1, 2012Assignee: Celera CorporationInventors: Dong Fang, Paul Moore, Steve Ruben, Sudeepta Aggarwal
-
Patent number: 8168603Abstract: The present invention concerns particular G-quartet oligonucleotides that are employed for the treatment and/or prevention of cancer. In specific cases, the G-quartet oligonucleotides inhibit HIF-1?.Type: GrantFiled: May 9, 2008Date of Patent: May 1, 2012Assignee: Baylor College of MedicineInventors: Naijie Jing, Yongli Guan
-
Patent number: 8158352Abstract: The invention concerns methods of screening for a hepatic syndrome occurring in the young adult and associating cholesterol biliary microlithiasis, intrahepatic cholestasis and several mutations of the MDR3 gene. The invention is also directed to methods for the treatment of said syndrome. The hepatic syndrome screening methods comprise detecting, from a nucleic acid sample extracted from peripheral blood mononucleate cells, heterozygous mutations of the MDR3 gene and/or homozygous mutations of the MDR3 gene that do not eliminate the expression of the protein expressed by the MDR3 gene, which has phosphatidylcholine carrier activity, in adult subjects associating cholesterol biliary microlithiasis and intrahepatic cholestasis.Type: GrantFiled: January 6, 2011Date of Patent: April 17, 2012Assignee: Assistance Publique-Hopitaux de ParisInventors: Raoul Poupon, Brigitte Hermelin, Olivier Rosmorduc
-
Patent number: 8148082Abstract: The invention provides isolated nucleic and amino acid sequences of a taste cell receptor that serves as a sensor for the bitter taste of phenylthiocarbamide (PTC), antibodies to such PTC taste receptor, methods of detecting such nucleic and amino acid sequences, and methods of screening for modulators of such PTC taste receptor.Type: GrantFiled: January 20, 2010Date of Patent: April 3, 2012Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, The University of Utah Research FoundationInventors: Dennis Drayna, Un-Kyung Kim, Mark Leppert
-
Publication number: 20120077685Abstract: The disclosure provides compositions and methods for identifying a cancer patient suitable or not suitable for a therapy that includes administration of a pyrimidine antimetabolite such as 5-fluorouracil. After determining if a patient is likely to be successfully treated, the disclosure also provides methods for treating these patients.Type: ApplicationFiled: July 14, 2011Publication date: March 29, 2012Inventor: Heinz-Josef Lenz
-
Patent number: 8142762Abstract: The present invention relates to methods of using GPR101 G protein-coupled receptor (GPCR) to screen candidate compounds as modulators of hypothalamic proopiomelanocortin (POMC)-derived biologically active peptide secretion. Modulators of GPR101 receptor modulate hypothalamic POMC-derived biologically active peptide secretion and are useful in the treatment of POMC-derived biologically active peptide-related disorders. POMC-derived biologically active peptides include, but are not limited to, ?-melanocyte stimulating hormone (?-MSH), ?-melanocyte stimulating hormone (?-MSH) and ?-melanocyte stimulating hormone (?-MSH). Agonists and partial agonists of GPR101 receptor stimulate hypothalamic ?-MSH, ?-MSH and ?-MSH secretion and are useful, for example, in the treatment and prevention of obesity and conditions related thereto (including but not limited to Type 2 diabetes, insulin resistance, and metabolic syndrome), inflammation-associated disorders, and pyrexia.Type: GrantFiled: May 30, 2007Date of Patent: March 27, 2012Assignee: Arena Pharmaceuticals, Inc.Inventor: Didier Bagnol
-
Patent number: 8143005Abstract: The present invention relates to epilepsy. More particularly, the present invention relates to idiopathic generalized epilepsy (IGE) and to the identification of three genes mapping to chromosome 2, which show mutations in patients with epilepsy. The invention further relates to nucleic acid sequences, and protein sequences of these loci (SCNA) and to the use thereof to assess, diagnose, prognose or treat epilepsy, to predict an epileptic individual's response to medication and to identify agents which modulate the function of the SCNA. The invention also provides screening assays using SCN1A, SCN2A and/or SCN3A which can identify compounds which have therapeutic benefit for epilepsy and related neurological disorders.Type: GrantFiled: December 14, 2009Date of Patent: March 27, 2012Assignee: McGill UniversityInventors: Guy A. Rouleau, Ronald G. Lafrenière, Daniel Rochefort
-
Publication number: 20120071542Abstract: This invention relates to the application of the highly conserved sequences of viral genome, especially from a highly conserved domain of enteroviral genome as templates to design target small ligand RNAs (sliRNAs). The resulting sliRNAs are therapeutically active ingredients in the treatment of the related diseases caused by pathological angiogenesis.Type: ApplicationFiled: September 20, 2010Publication date: March 22, 2012Applicant: Biomics Biotechnologies Co., LtdInventors: York YuanYuan Zhu, Li Chen, TieJun Li, YiXiang Lu, YunCheng Sun, Jinkang Wang
-
Publication number: 20120040367Abstract: The present invention discloses construct systems and methods for comparing different iso-accepting codons according to their preference for translating RNA transcripts into proteins in cell or tissues of interest or for producing a selected phenotype in an organism of interest or part thereof. The codon preference comparisons thus obtained are particularly useful for modifying the translational efficiency of protein-encoding polynucleotides in cells or tissues of interest or for modulating the quality of a selected phenotype conferred by a phenotype-associated polypeptide upon an organism of interest or part thereof.Type: ApplicationFiled: October 2, 2008Publication date: February 16, 2012Applicant: THE UNIVERSITY OF QUEENSLANDInventor: Ian Hector Frazer
-
Patent number: 8114593Abstract: Using gene expression analysis, specific biomarker genes and gene products have been identified which are activated in transformed cells, but suppressed in nontransformed cells; or suppressed in transformed cells, but activated in transformed cells affected by Contact Normalization. Thus, the present invention features compositions and methods for detecting, diagnosing, treating and prognosing cancer.Type: GrantFiled: March 11, 2009Date of Patent: February 14, 2012Assignee: University of Medicine and Dentistry of New JerseyInventors: Gary S. Goldberg, Yongquan Shen
-
Patent number: 8110364Abstract: Methods of diagnosing or monitoring an autoimmune or chronic inflammatory disease, particularly SLE in a patient by detecting the expression level of one or more genes or surrogates derived therefrom in the patient are described. Diagnostic oligonucleotides for diagnosing or monitoring chronic inflammatory disease, particularly SLE infection and kits or systems containing the same are also described.Type: GrantFiled: December 1, 2010Date of Patent: February 7, 2012Assignee: XDx, Inc.Inventors: Jay Wohlgemuth, Kirk Fry, Robert Woodward, Ngoc Ly
-
Publication number: 20120029180Abstract: The invention relates to an isolated or recombinant Na?/H+ exchanger comprising an isolated or recombinant Na+/H+ exchanger, particularly to the PBO-4 Na+/H+ exchanger. Also disclosed is an isolated or recombinant protein component of an H+-grated channel which can be affected by extracellular Ca2+ concentration. In particular, the invention relates to PBO-5 and/or PBO-8 and/or a H+-gated channel composed of PBO-5 and PBO-8. The invention relates to compounds isolated from a vertebrate organism, wherein said compounds comprise at least a part of a H+-gated channel or Na+/H+ exchanger. The invention also relates to a method for identifying a component of a H+-grated channel in a vertebrate organism.Type: ApplicationFiled: August 17, 2011Publication date: February 2, 2012Inventors: Erik M. Jorgensen, Asim A. Beg, Paola Nix
-
Publication number: 20120028264Abstract: Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.Type: ApplicationFiled: July 25, 2011Publication date: February 2, 2012Inventors: Steven Shak, Frederick L. Baehner, Tara Maddala, Mark Lee, Robert J. Pelham, Wayne Cowens, Diana Cherbavaz, Michael C. Kiefer, Michael Crager, Audrey Goddard, Joffre B. Baker
-
Patent number: 8101349Abstract: The present invention provides polynucleotides, as well as polypeptides encoded thereby, that are differentially expressed in cancer cells. These polynucleotides are useful in a variety of diagnostic and therapeutic methods. The present invention further provides methods of reducing growth of cancer cells. These methods are useful for treating cancer.Type: GrantFiled: February 12, 2004Date of Patent: January 24, 2012Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Pablo Dominguez Garcia, Altaf Kassam, George Lamson
-
Patent number: 8101361Abstract: The present invention is related to the novel discovery of a number of genes that were identified as systemic markers of pulmonary inflammation. This discovery allows for development of a novel tool for reliable, rapid and efficient assessment of therapeutic responses and enables design of novel therapies targeted against diseases associated with pulmonary inflammation. In one embodiment, the present invention allows quantification of therapeutic response in patients who have a disease associated with pulmonary inflammation. In preferred embodiments, the genes are CD64, ADAM9, CD36, IL32, HPSE, PLXND1, HCA112, CSPG2, TLR2, and CD163.Type: GrantFiled: March 10, 2009Date of Patent: January 24, 2012Assignee: National Jewish HealthInventors: Milene Saavedra, Jerry Nick
-
Patent number: 8093004Abstract: Present invention relates to a method for predicting an individual's bronchodilatory response to a ? agonist. Present invention particularly relates to the detection of specific allelic variants of the ?2AR gene and their use as pharmacogenetic markers towards response to ? agonist.Type: GrantFiled: April 28, 2004Date of Patent: January 10, 2012Assignees: Council of Scientific & Industrial Research, Piramal Life Sciences LimitedInventors: Ritushree Kukreti, Pallav Bhatnagar, Chandrika Rao, Balram Ghosh, Samir Kumar Brahmachari, Randeep Guleria, Chinmoyee Das
-
Patent number: 8093286Abstract: The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the ?1-adrenergic receptor (AR).Type: GrantFiled: August 13, 2007Date of Patent: January 10, 2012Assignee: The Regents of the University of Colorado, a body corporateInventors: Stephen B. Liggett, Michael Bristow
-
Publication number: 20120004185Abstract: Isolated polypeptides comprising or consisting essentially of specific structural motifs (e.g., three ?-sheets and two ?-helices) are provided, wherein the polypeptides exhibit at least one cell signaling and/or other non-canonical activity of biological relevance. Also provided are polynucleotides encoding such polypeptides, binding agents that bind such polypeptides, analogs, variants and fragments of such polypeptides, etc., as well as compositions and methods of identifying and using any of the foregoing.Type: ApplicationFiled: February 26, 2010Publication date: January 5, 2012Applicant: ATYR PHARMA, INC.Inventor: Leslie Ann Greene
-
Patent number: 8088584Abstract: The invention provides LTBP2, which is associated with cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of LTBP2 as well as pharmaceutical compositions comprising such compounds. The invention also provides LTBP2 as a biomarker for diseases such as cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases.Type: GrantFiled: October 2, 2007Date of Patent: January 3, 2012Assignee: Bayer Schering Pharma AktiengesellschaftInventors: Stefan Golz, Holger Summer, Andreas Geerts, Ulf Brüggemeier, Barbara Albrecht-Küpper, Martina Klein, Sonja Steppan, Peter Ellinghaus, Donatella D'Urso, Michael Seewald, Hendrik Milting
-
Patent number: 8080578Abstract: The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the ?1-adrenergic receptor (AR).Type: GrantFiled: August 13, 2007Date of Patent: December 20, 2011Assignee: The Regents of the University of Colorado, a body corporateInventors: Stephen B. Liggett, Michael Bristow
-
Publication number: 20110306043Abstract: The invention features devices and methods for detecting, enriching, and analyzing circulating tumor cells and other particles. The invention further features methods of diagnosing a condition, e.g., cancer, in a subject by analyzing a cellular sample from the subject.Type: ApplicationFiled: July 9, 2009Publication date: December 15, 2011Applicant: The General Hospital CorporationInventors: MARTIN FUCHS, MEHMET TONER, YI-SHUIAN HUANG, NEIL X. KRUEGER, DANIEL A. HABER
-
Patent number: 8076073Abstract: The present invention sterol-modified hedgehog polypeptides and functional fragments thereof. Methods of identifying compositions which affect hedgehog activity based on inhibition of cholesterol modification of hedgehog protein are described. In one aspect of the invention, the method provides a means for affecting cholesterol biosynthesis or transport in a cell comprising contacting a cell with an effective amount of a compound that affects hedgehog, thereby affecting cholesterol biosynthesis or transport. The effect may be inhibition or stimulation of cholesterol biosynthesis or transport.Type: GrantFiled: May 20, 2003Date of Patent: December 13, 2011Assignee: The Johns Hopkins University School of MedicineInventors: Philip A. Beachy, Jeffrey A. Porter, Michael K. Cooper
-
Publication number: 20110301227Abstract: This application relates to the use of agents such as expression vectors and nucleic acids encoding integrins ?6A or ?6B as well as antibodies specific for those integrins which are capable of modulating the ratio between the B and A isoforms of the ?6 integrin in the treatment of diseases associated with an altered proliferation rate, such as cancer. The application also relates to the use of the ratio between the B and A isoforms of the ?6 integrin in the diagnosis of diseases associated with an altered proliferation rate.Type: ApplicationFiled: December 10, 2009Publication date: December 8, 2011Inventors: Jean-Francois Beaulieu, Elizabeth Herring, Nuria Basora, Jean-Francois Groulx
-
Patent number: 8071304Abstract: The present invention discloses a functional relationship between a recognized disease condition and a polymorphism in the nucleotide factor kappa B promoter (NFKB1). This relationship provides a platform for methods of altering promoter activity and for determining similar relationships between specific pathologies and identified polymorphisms. A statistically significant risk of developing ulcerative colitis was shown to be correlated with the presence of an ATTG insertion/deletion in the NFKB1 promoter and is likely to apply also to a variety of other inflammatory diseases.Type: GrantFiled: April 5, 2004Date of Patent: December 6, 2011Assignee: The Johns Hopkins UniversityInventors: Steven R. Brant, Amir Karban, Franklin Nouvet, Theodore M. Bayless, James J. Potter, Esteban Mezey, Toshihiko Okazaki
-
Patent number: 8071307Abstract: The present invention provides a method of discriminating a relative risk for the morbidity of atopic dermatitis of a test subject comprising: analyzing gene polymorphism of two or more of genes related to onset of atopic dermatitis using a sample isolated from a statistically significant number of normal persons and patients of atopic dermatitis to determine relative ratios (percentages (%)) related to the individual gene polymorphism of individual derived from the analysis; and calculating an odds ratio according to specified gene polymorphism from the relative ratio; and using, as a discrimination criterion, a combination of two or more of gene polymorphisms showing a synergetically higher odds ratio than odds ratios according to individual gene polymorphism.Type: GrantFiled: April 3, 2006Date of Patent: December 6, 2011Assignee: Asubio Pharma Co., Ltd.Inventors: Keiko Tanaka, Julian M. Hopkin
-
Publication number: 20110287025Abstract: The present invention relates to a method for determining a subject's resistance to treatment with 2,2-dimethyl-N—((S)-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)-N?-(2,2,3,3,3-pentafluoro-propyl)-malonamide by measuring the levels a biomarker or biomarkers present in a biological sample obtained from the subject, the biomarker being IL6 and/or IL8. The present invention also relates to a combination therapy for a patient suffering from a proliferative disorder comprising administering to the patient 2,2-Dimethyl-N—((S)-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)-N?-(2,2,3,3,3-pentafluoro-propyl)-malonamide and an anti-IL6 and/or an anti-IL8 agent.Type: ApplicationFiled: May 2, 2011Publication date: November 24, 2011Inventors: John Frederick Boylan, Wei He
-
Publication number: 20110287963Abstract: One aspect of the present invention relates to a reporter system for detection of protein-protein interactions in the periplasm of a prokaryotic host cell. The reporter system includes a first expression system which has a nucleic acid molecule encoding a first fragment of a reporter protein molecule, a nucleic acid molecule encoding a first signal sequence, and a nucleic acid molecule encoding a first member of a putative binding pair, where the nucleic acid molecule encoding the first fragment, the nucleic acid molecule encoding the first signal sequence, and the nucleic acid molecule encoding the first member of the putative binding pair are operatively coupled to permit their expression in a prokaryotic host cell as a first fusion protein.Type: ApplicationFiled: November 16, 2009Publication date: November 24, 2011Applicant: CORNELL UNIVERSITYInventors: Matthew P. Delisa, Thomas Mansell
-
Publication number: 20110287957Abstract: The invention pertains to a method for early detection and screening of colorectal cancer in human subjects based on RNA isolated from blood obtained from said subject. According to the invention, the expression of at least 3, 5, 8, 30, 60, 102, 202, 55, 1002 or 1002 RNAs listed in Tables 1-15 are measured. Using the invention, an accurate and noninvasive screening and diagnosis tool for colorectal cancer is provided with a sensitivity of at least 80% and a specificity of 85% that has high clinical utility and the potential for broad adoption.Type: ApplicationFiled: May 19, 2011Publication date: November 24, 2011Applicant: Signature Diagnostics AGInventors: Andre Rosenthal, Bernd Hinzmann, Tobias Mayr, Hans-Peter Adams